Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Mar 20257:11 amRNSBoard Changes
27th Mar 20257:08 amRNSHalf year results and financial report
26th Mar 20258:15 amRNSHolding(s) in Company
24th Mar 20257:00 amRNS-RNew Technology and Safety Leadership Appointments
21st Mar 20257:59 amRNSLondon Town Hall presentation to be live streamed
3rd Mar 202510:18 amRNSNotification of Major Holdings
27th Feb 20257:00 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSH1 FY2025 Trading Update & Quarterly KPIs
24th Feb 20257:00 amRNSMitsubishi Electric Automotive America Agreement
18th Feb 20257:00 amRNSLondon Presentation
23rd Jan 20257:00 amRNSDirector dealing
21st Jan 20257:00 amRNSDirector/PDMR Shareholding
20th Jan 20257:00 amRNSDirector/PDMR Shareholding
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
14th Jan 20257:11 amRNSDirector/PDMR Shareholding
10th Jan 20257:00 amRNSPDMR / Director Dealing
3rd Jan 20257:00 amRNSHolding(s) in Company
31st Dec 202412:27 pmRNSHolding(s) in Company
31st Dec 20248:00 amRNSPDMR/PCA Dealing
31st Dec 20248:00 amRNSDirector/PDMR Shareholding
31st Dec 20248:00 amRNSDirector/PDMR Shareholding
31st Dec 20248:00 amRNSHolding(s) in Company
30th Dec 20247:00 amRNSHolding(s) in Company
30th Dec 20247:00 amRNSDirector/PDMR Shareholding
23rd Dec 20247:00 amRNS£26.2 million strategic investment from Mitsubishi
19th Dec 20247:00 amRNSIssue of Equity and Total Voting Rights
12th Dec 20243:00 pmRNSFY2024 Annual Report
4th Dec 20247:00 amRNS-RLaunch of 2023-24 Guardian Insights Report
27th Nov 20248:49 amRNSResult of AGM
21st Nov 20248:30 amRNSIssue of Shares and Total Voting Rights
11th Nov 20247:00 amRNSQ1 FY2025 Quarterly KPIs
4th Nov 20247:00 amRNSNotice of Annual General Meeting
31st Oct 20247:00 amRNSGlobal regulatory momentum drives revenue growth
17th Oct 20247:00 amRNSNotice of Full Year Results 2024
28th Aug 20247:00 amRNSSeeing Machines FY24 Trading Update
8th Aug 20247:00 amRNSSeeing Machines (SEE) Q4 FY2024 Quarterly KPIs
8th Jul 20247:00 amRNSSeeing Machines acquires Asaphus Vision GmbH
26th Jun 20247:00 amRNSFive year License Renewal with Caterpillar
7th May 20247:00 amRNSQ3 FY2024 Quarterly KPIs
2nd May 202410:30 amRNSDirector/PDMR Shareholding
1st May 20247:00 amRNSAutomotive Program Extension to 2032
26th Apr 202411:00 amRNSDirector/PDMR Shareholding
25th Mar 20248:06 amRNSDirector/PDMR Shareholding
18th Mar 20247:00 amRNSHalf year results and financial report
28th Feb 20247:00 amRNSNotice of Results
8th Feb 20247:00 amRNSH1 FY2024 Trading Update & Quarterly KPIs
10th Jan 20247:00 amRNSNew Orders for Guardian Generation 3
9th Jan 20247:00 amRNSSeeing Machines unveils latest Guardian technology
3rd Jan 20247:00 amRNSSeeing Machines to showcase technology at CES 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.